Long‐term outcomes of staged liver resection for synchronous liver metastases from colorectal cancer and the clinical impact of early recurrence: A single‐center retrospective cohort study

Abstract

Abstract Aim This study was undertaken to evaluate the long‐term outcomes of staged liver resection for synchronous liver metastases (SLM) from colorectal cancer (CRC), and to elucidate the prognostic impact and predictors of early recurrence (ER), which was defined as recurrence within 6 mo. Methods Patients with SLM from CRC, except for initially unresectable SLM, from January 2013 to December 2020 were included. First, overall survival (OS) and relapse‐free survival (RFS) after staged liver resection were evaluated. Second, eligible patients were classified as follows: patients who were unresectable after resection of CRC (UR), patients with ER, and patients without ER (non‐ER), and their OS after resection of CRC were compared. In addition, risk factors for ER were identified. Results The 3‐y OS and RFS rates after resection of SLM were 78.8% and 30.8%, respectively. Next, the eligible patients were classified as follows: ER (N = 24), non‐ER (N = 56), and UR (N = 24). The non‐ER group had a significantly better OS than the ER (3‐y OS: 89.7% vs 48.0%, P = .001) and UR (3‐y OS: 89.7% vs 61.6%, P < .001) groups, while there was no significant difference between the ER and UR groups in OS (3‐y OS: 48.0% vs 61.6%, P = .638). Increasing carcinoembryonic antigen (CEA) before and after resection of CRC was identified as an independent risk factor for ER. Conclusion Staged liver resection for SLM from CRC was feasible and useful for oncological evaluation, as changes in CEA could predict ER, which was associated with a poor prognosis.

Keywords

• carcinoembryonic antigen
• colorectal cancer
• early recurrence
• liver metastasis
• staged liver resection